| 发明名称 | Forms of rifaximin and uses thereof | ||
| 摘要 | The present invention relates to new rifaximin forms kappa, theta, rifaximin:piperazine cocrystal 1 and rifaximin:piperazine cocrystal 2, methods of making same and to their use in medicinal preparations and therapeutic methods. | ||
| 申请公布号 | US8815888(B2) | 申请公布日期 | 2014.08.26 |
| 申请号 | US201313955660 | 申请日期 | 2013.07.31 |
| 申请人 | Salix Pharmaceuticals, Ltd. | 发明人 | Wu Yiduo;Parent Stephan D.;Schultheiss Nathan Carl;Bevill Melanie Janelle;Vlahova Petinka;Houston Travis L. |
| 分类号 | C07D498/22;A61K31/04 | 主分类号 | C07D498/22 |
| 代理机构 | McCarter & English, LLP | 代理人 | McCarter & English, LLP ;Sparks Jonathan M. |
| 主权项 | 1. A rifaximin polymorph Form kappa, wherein the polymorph Form kappa exhibits an X-ray powder diffraction pattern having characteristic peaks expressed in degrees 2θ at 5.41-5.65, 6.45-6.67, 6.83-6.94, 7.03-7.06, and 7.52-7.56; 6.45-6.67, 6.83-6.94, 7.03-7.06, 7.68-7.78, and 18.46-18.61; 5.41-5.65, 6.45-6.67, 6.83-6.94, 7.03-7.06, 7.52-7.56, and 18.46-18.61; or 6.45-6.67, 6.45-6.67, 6.83-6.94, 7.03-7.06, 7.68-7.78, and 18.46-18.61. | ||
| 地址 | Raleigh NC US | ||